ESR1 and interstitial lung disease: ILD: 82.8% received immunosuppressants (MMF, CYC, rituximab). PAH: 82.8% received PAH-targeted therapy - Monotherapy: PDE5i or ERA - Combination: 31% dual (PDE5i + ERA), 13.8% triple (incl. prostacyclins)